Advanced search
1 file | 956.76 KB Add to list

Serum anti-GM2 and anti-GalNAc-GD1a IgG antibodies are biomarkers for acute canine polyradiculoneuritis

Author
Organization
Abstract
Objectives A previous single-country pilot study indicated serum anti-GM2 and anti-GA1 anti-glycolipid antibodies as potential biomarkers for acute canine polyradiculoneuritis. This study aims to validate these findings in a large geographically heterogenous cohort. Materials and Methods Sera from 175 dogs clinically diagnosed with acute canine polyradiculoneuritis, 112 dogs with other peripheral nerve, cranial nerve or neuromuscular disorders and 226 neurologically normal dogs were screened for anti-glycolipid antibodies against 11 common glycolipid targets to determine the immunoglobulin G anti-glycolipid antibodies with the highest combined sensitivity and specificity for acute canine polyradiculoneuritis. Results Anti-GM2 anti-glycolipid antibodies reached the highest combined sensitivity and specificity (sensitivity: 65.1%, 95% confidence interval 57.6 to 72.2%; specificity: 90.2%, 95% confidence interval 83.1 to 95.0%), followed by anti-GalNAc-GD1a anti-glycolipid antibodies (sensitivity: 61.7%, 95% confidence interval 54.1 to 68.9%; specificity: 89.3%, 95% confidence interval 82.0 to 94.3%) and these anti-glycolipid antibodies were frequently present concomitantly. Anti-GA1 anti-glycolipid antibodies were detected in both acute canine polyradiculoneuritis and control animals. Both for anti-GM2 and anti-GalNAc-GD1a anti-glycolipid antibodies, sex was found a significantly associated factor with a female to male odds ratio of 2.55 (P=0.0096) and 3.00 (P=0.0198), respectively. Anti-GalNAc-GD1a anti-glycolipid antibodies were more commonly observed in dogs unable to walk (odds ratio 4.56; P=0.0076). Clinical Significance Anti-GM2 and anti-GalNAc-GD1a immunoglobulin G anti-glycolipid antibodies represent serum biomarkers for acute canine polyradiculoneuritis.
Keywords
GUILLAIN-BARRE-SYNDROME, ANTIGANGLIOSIDE ANTIBODY, GANGLIOSIDE, ANTIBODIES, DEMYELINATING POLYNEUROPATHY, IDIOPATHIC POLYNEUROPATHY, COMPLEMENT, NEUROPATHY, DOGS, DESTRUCTION, GALNAC-GD1A

Downloads

  • (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 956.76 KB

Citation

Please use this url to cite or link to this publication:

MLA
Halstead, S. K., et al. “Serum Anti-GM2 and Anti-GalNAc-GD1a IgG Antibodies Are Biomarkers for Acute Canine Polyradiculoneuritis.” JOURNAL OF SMALL ANIMAL PRACTICE, vol. 63, no. 2, 2022, pp. 104–12, doi:10.1111/jsap.13439.
APA
Halstead, S. K., Gourlay, D. S., Penderis, J., Bianchi, E., Dondi, M., Wessmann, A., … Rupp, A. (2022). Serum anti-GM2 and anti-GalNAc-GD1a IgG antibodies are biomarkers for acute canine polyradiculoneuritis. JOURNAL OF SMALL ANIMAL PRACTICE, 63(2), 104–112. https://doi.org/10.1111/jsap.13439
Chicago author-date
Halstead, S. K., D. S. Gourlay, J. Penderis, E. Bianchi, M. Dondi, A. Wessmann, M. Musteata, et al. 2022. “Serum Anti-GM2 and Anti-GalNAc-GD1a IgG Antibodies Are Biomarkers for Acute Canine Polyradiculoneuritis.” JOURNAL OF SMALL ANIMAL PRACTICE 63 (2): 104–12. https://doi.org/10.1111/jsap.13439.
Chicago author-date (all authors)
Halstead, S. K., D. S. Gourlay, J. Penderis, E. Bianchi, M. Dondi, A. Wessmann, M. Musteata, M. Le Chevoir, L. Martinez-Anton, Sofie Bhatti, H. Volk, I Mateo, A. Tipold, E. Ives, A. Pakozdy, R. Gutierrez-Quintana, J. Brocal, Z. Whitehead, N. Granger, P. Pazzi, T. Harcourt-Brown, R. Jose-Lopez, S. Rupp, H. C. Schenk, P. Smith, C. Gandini, M. Menchetti, V Mortera-Balsa, C. Rusbridge, A. Tauro, F. Cozzi, M. Deutschland, F. Tirrito, P. Freeman, M. Lowrie, M. R. Jackson, H. J. Willison, and A. Rupp. 2022. “Serum Anti-GM2 and Anti-GalNAc-GD1a IgG Antibodies Are Biomarkers for Acute Canine Polyradiculoneuritis.” JOURNAL OF SMALL ANIMAL PRACTICE 63 (2): 104–112. doi:10.1111/jsap.13439.
Vancouver
1.
Halstead SK, Gourlay DS, Penderis J, Bianchi E, Dondi M, Wessmann A, et al. Serum anti-GM2 and anti-GalNAc-GD1a IgG antibodies are biomarkers for acute canine polyradiculoneuritis. JOURNAL OF SMALL ANIMAL PRACTICE. 2022;63(2):104–12.
IEEE
[1]
S. K. Halstead et al., “Serum anti-GM2 and anti-GalNAc-GD1a IgG antibodies are biomarkers for acute canine polyradiculoneuritis,” JOURNAL OF SMALL ANIMAL PRACTICE, vol. 63, no. 2, pp. 104–112, 2022.
@article{8748928,
  abstract     = {{Objectives A previous single-country pilot study indicated serum anti-GM2 and anti-GA1 anti-glycolipid antibodies as potential biomarkers for acute canine polyradiculoneuritis. This study aims to validate these findings in a large geographically heterogenous cohort. Materials and Methods Sera from 175 dogs clinically diagnosed with acute canine polyradiculoneuritis, 112 dogs with other peripheral nerve, cranial nerve or neuromuscular disorders and 226 neurologically normal dogs were screened for anti-glycolipid antibodies against 11 common glycolipid targets to determine the immunoglobulin G anti-glycolipid antibodies with the highest combined sensitivity and specificity for acute canine polyradiculoneuritis. Results Anti-GM2 anti-glycolipid antibodies reached the highest combined sensitivity and specificity (sensitivity: 65.1%, 95% confidence interval 57.6 to 72.2%; specificity: 90.2%, 95% confidence interval 83.1 to 95.0%), followed by anti-GalNAc-GD1a anti-glycolipid antibodies (sensitivity: 61.7%, 95% confidence interval 54.1 to 68.9%; specificity: 89.3%, 95% confidence interval 82.0 to 94.3%) and these anti-glycolipid antibodies were frequently present concomitantly. Anti-GA1 anti-glycolipid antibodies were detected in both acute canine polyradiculoneuritis and control animals. Both for anti-GM2 and anti-GalNAc-GD1a anti-glycolipid antibodies, sex was found a significantly associated factor with a female to male odds ratio of 2.55 (P=0.0096) and 3.00 (P=0.0198), respectively. Anti-GalNAc-GD1a anti-glycolipid antibodies were more commonly observed in dogs unable to walk (odds ratio 4.56; P=0.0076). Clinical Significance Anti-GM2 and anti-GalNAc-GD1a immunoglobulin G anti-glycolipid antibodies represent serum biomarkers for acute canine polyradiculoneuritis.}},
  author       = {{Halstead, S. K. and Gourlay, D. S. and Penderis, J. and Bianchi, E. and Dondi, M. and Wessmann, A. and Musteata, M. and Le Chevoir, M. and Martinez-Anton, L. and Bhatti, Sofie and Volk, H. and Mateo, I and Tipold, A. and Ives, E. and Pakozdy, A. and Gutierrez-Quintana, R. and Brocal, J. and Whitehead, Z. and Granger, N. and Pazzi, P. and Harcourt-Brown, T. and Jose-Lopez, R. and Rupp, S. and Schenk, H. C. and Smith, P. and Gandini, C. and Menchetti, M. and Mortera-Balsa, V and Rusbridge, C. and Tauro, A. and Cozzi, F. and Deutschland, M. and Tirrito, F. and Freeman, P. and Lowrie, M. and Jackson, M. R. and Willison, H. J. and Rupp, A.}},
  issn         = {{0022-4510}},
  journal      = {{JOURNAL OF SMALL ANIMAL PRACTICE}},
  keywords     = {{GUILLAIN-BARRE-SYNDROME,ANTIGANGLIOSIDE ANTIBODY,GANGLIOSIDE,ANTIBODIES,DEMYELINATING POLYNEUROPATHY,IDIOPATHIC POLYNEUROPATHY,COMPLEMENT,NEUROPATHY,DOGS,DESTRUCTION,GALNAC-GD1A}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{104--112}},
  title        = {{Serum anti-GM2 and anti-GalNAc-GD1a IgG antibodies are biomarkers for acute canine polyradiculoneuritis}},
  url          = {{http://dx.doi.org/10.1111/jsap.13439}},
  volume       = {{63}},
  year         = {{2022}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: